000			01913 a2200517 4500
005			20250515150729.0
264		0	_c20090528
008			200905s 0 0 eng d
022			_a1098-1004
024	7		_a10.1002/humu.20855 _2doi
040			_aNLM _beng _cNLM
100	1		_aRosenberger, Georg
245	0	0	_aOncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. _h[electronic resource]
260			_bHuman mutation _cMar 2009
300			_a352-62 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAbnormalities, Multiple _xgenetics
650	0	4	_aCells, Cultured
650	0	4	_aChromones _xpharmacology
650	0	4	_aCraniofacial Abnormalities
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aEpidermal Growth Factor _xpharmacology
650	0	4	_aFailure to Thrive _xpathology
650	0	4	_aFibroblasts _xdrug effects
650	0	4	_aGuanosine Triphosphate _xmetabolism
650	0	4	_aHumans
650	0	4	_aImmunoblotting
650	0	4	_aIntellectual Disability _xpathology
650	0	4	_aMAP Kinase Kinase 1 _xmetabolism
650	0	4	_aMAP Kinase Kinase 2 _xmetabolism
650	0	4	_aMorpholines _xpharmacology
650	0	4	_aMutation
650	0	4	_aPhosphatidylinositol 3-Kinases _xmetabolism
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aProto-Oncogene Proteins p21(ras) _xgenetics
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSkin _xdrug effects
650	0	4	_aSkin Abnormalities
650	0	4	_aSyndrome
700	1		_aMeien, Stefanie
700	1		_aKutsche, Kerstin
773	0		_tHuman mutation _gvol. 30 _gno. 3 _gp. 352-62
856	4	0	_uhttps://doi.org/10.1002/humu.20855 _zAvailable from publisher's website
999			_c18491092 _d18491092